Covered recipient · General Payments record
CHARLES W STAFFORD
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2023–2024
$382.57
- Reported across 21 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $294.75 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Acerta Pharma LLC | $64.57 | 4 |
| Novo Nordisk AS | $47.98 | 3 |
| Abbott Laboratories | $42.26 | 2 |
| ABBVIE INC. | $36.55 | 2 |
| Amgen Inc. | $33.69 | 2 |
| GlaxoSmithKline, LLC. | $23.23 | 1 |
| EISAI INC. | $17.13 | 1 |
| Lilly USA, LLC | $16.01 | 1 |
| Exact Sciences Corporation | $13.33 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $22.84 | 04/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125107064 | CMS |
| Abbott Laboratories | $19.42 | 07/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125107066 | CMS |
| ABBVIE INC. | $16.72 | 01/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106152019 | CMS |
| ABBVIE INC. | $19.83 | 04/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106152021 | CMS |
| Amgen Inc. | $17.57 | 07/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117390074 | CMS |
| Amgen Inc. | $16.12 | 09/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117390076 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.65 | 02/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105809889 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.29 | 04/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105704798 | CMS |
| AstraZeneca Pharmaceuticals LP | $17.21 | 06/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104368377 | CMS |
| AstraZeneca Pharmaceuticals LP | $17.42 | 07/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105485807 | CMS |
| Eisai Inc. | $17.13 | 12/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110736205 | CMS |
| Exact Sciences Corporation | $13.33 | 10/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114914818 | CMS |
| GlaxoSmithKline, LLC. | $23.23 | 09/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115858298 | CMS |
| Lilly USA, LLC | $16.01 | 06/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136096297 | CMS |
| Novo Nordisk Inc | $19.90 | 03/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097462147 | CMS |
| Novo Nordisk Inc | $14.29 | 09/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097590741 | CMS |
| Novo Nordisk Inc | $13.79 | 10/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096897845 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2023, 2024
- Source files
- Dataset page · Bulk file · PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.